Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile

Investigational New Drugs

Volumn 25, Issue 6, 2007, Pages 525-533

  Vasconcelos, F C ^a   Gattass, C R ^b   Rumjanek, V M ^b   Maia, R C ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Apoptosis; Chronic myeloid leukemia; MRP; Multidrug resistance; P glycoprotein; Pomolic acid

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; OLEANOLIC ACID; POMOLIC ACID; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG RESISTANCE; HUMAN; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLAST CRISIS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; LEUKEMIA, MYELOID, CHRONIC-PHASE; OLEANOLIC ACID;

EID: 39549084587     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-007-9064-5     Document Type: Article

References (32)

1. Deininger MWN, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343-3356
2. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. (2001) European Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France Intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98:3074-3081
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037 (Pubitemid 32267972)
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880 (Pubitemid 32743979)
5. Illmer T, SchaichM, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M, Pursche S, Bergemann T, Ehninger G, Schleyer E (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18:401-408 (Pubitemid 38425851)
6. Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29 (Pubitemid 36078452)
7. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 10:2368-2373 (Pubitemid 36304670)
8. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K (2005) Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4:747-752 (Pubitemid 41351174)
9. List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, Dakhil SR, Appelbaum FR (2002) Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 100:1910-1912 (Pubitemid 34925173)
10. Ehrhardt H, Fulda S, Fuhrer M, Debatin KM, Jeremias I (2004) Betulinic acid-induced apoptosis in leukemia cells. Leukemia 18 (8):1406-1412, Aug (Pubitemid 39136751)
11. Fernandes J, Castilho RO, Costa MR, Wagner-Souza K, Kaplan MAC, Gattass CR (2003) Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett 190:165-169 (Pubitemid 36136015)
12. Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos LF, Maia RC, Capella MA (2001) Multidrug resistance in tumor cells: characterization of the multidrug resistance line K562-Lucena 1. Ann Acad Bras Cienc 73:57-69
13. Fernandes J, Weinlich R, Castilho RO, Kaplan MAC, Amarante-Mendes GP, Gattass CR (2005) Pomolic acid triggers mitochondria-dependent apoptotic cell death in leukemia cell line. Cancer Lett 219:49-55 (Pubitemid 40203170)
14. Fernandes J, Weinlich R, Castilho RO, Amarante-Mendes GP, Gattass CR (2007) Pomolic acid may overcome multidrug resistance mediated by overexpression of anti-apoptotic Bcl-2 proteins. Cancer Lett 245:315-332
15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, Sultan C, Cox C (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French - American- British Cooperative Leukaemia Group. Br J Haematol 87:746-754 (Pubitemid 24264647)
16. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F et al. (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799 (Pubitemid 14141296)
17. Silva KL, Vasconcelos FC, Marques-Santos LF, Kwee JK, Maia RC (2003) CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype. Leuk Res 27:243-251 (Pubitemid 36132114)
18. Silva KL, Vasconcellos DV, Castro ED, Coelho AM, Linden R, Maia RC (2006) Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 11:277-285 (Pubitemid 43291027)
19. Vasconcelos FC, Cavalcanti GB Jr, Silva KL, de Meis E, Kwee JK, Rumjanek VM, Maia RC (2007) Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res 31:445-454 (Pubitemid 46198938)
20. Cavalcanti GB Jr, da Cunha Vasconcelos F, Pinto de Faria G, Scheiner MA, de Almeida Dobbin J, Klumb CE, Maia RC (2004) Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry B Clin Cytom 61:1-8 (Pubitemid 39223364)
21. Michelutti A, Michieli M, Damiani D, Melli C, Geromin A, Russo D, Fanin R, Baccarani M (1994) Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Haematologica 79:200-204 (Pubitemid 24255764)
22. Trindade GS, Capella MA, Capella LS, Affonso-Mitidieri OR, Rumjanek VM (1999) Differences in sensitivity to UVC, UVB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein. Photochem Photobiol 69:694-699 (Pubitemid 129548830)
23. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW (2002) P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9:1266-1272 (Pubitemid 35331774)
24. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW (2004) Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differentiation 11:1028-1037 (Pubitemid 39232362)
25. Rosti G, Trabacchi E, Bassi S (2003) Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 88:256-259 (Pubitemid 36358712)
26. Larsen AK, Escargueil AE, Skladonowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217-229 (Pubitemid 30160791)
27. Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21-23
28. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P (1984) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157
29. Pepper C, Hoy T, Bentley DP (1997) Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 76:935-938 (Pubitemid 27401947)
30. Noutomi T, Chiba H, Itoh M, Toyota H, Mixuguichi J (2002) Bcl-xL confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol 38:41-48 (Pubitemid 34081210)
31. Shi X, Liu S, Kleeff J, Friess H, Buchler MW (2002) Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis regulating genes. Oncology 62:354-362 (Pubitemid 34914105)
32. Duvvuri M, Krise JP (2005) Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci 10:1499-1509 (Pubitemid 40529015)